MX2020012150A - Composiciones para inducir una respuesta inmunitaria. - Google Patents

Composiciones para inducir una respuesta inmunitaria.

Info

Publication number
MX2020012150A
MX2020012150A MX2020012150A MX2020012150A MX2020012150A MX 2020012150 A MX2020012150 A MX 2020012150A MX 2020012150 A MX2020012150 A MX 2020012150A MX 2020012150 A MX2020012150 A MX 2020012150A MX 2020012150 A MX2020012150 A MX 2020012150A
Authority
MX
Mexico
Prior art keywords
promoter
inducing
immune response
poxvirus
seq
Prior art date
Application number
MX2020012150A
Other languages
English (en)
Inventor
Adrian Vs Hill
Irina Redchenko
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2020012150A publication Critical patent/MX2020012150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)

Abstract

La invención se relaciona con una composición para inducir una respuesta inmunitaria mediada por células T para el tratamiento o prevención del cáncer de próstata que comprende un vector de virus Vaccinia Ankara modificado (MVA) que comprende el polipéptido del antígeno 5T4 en control de un promotor F11 de poxvirus. De manera adecuada, dicho promotor F11 de poxvirus es el promotor F11 endógeno de MVA. De manera más adecuada dicho vector expresa un polipéptido que tiene la secuencia de aminoácidos de la SEQ ID NO: 1 o dicho vector expresa un polipéptido codificado por un polinucleótido que tiene la secuencia de ácidos nucleicos de la SEQ ID NO: 2. La invención también se relaciona con los usos y métodos.
MX2020012150A 2018-05-16 2019-05-16 Composiciones para inducir una respuesta inmunitaria. MX2020012150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1807932.7A GB201807932D0 (en) 2018-05-16 2018-05-16 Compositions and methods for inducing an immune response
PCT/EP2019/062694 WO2019219851A1 (en) 2018-05-16 2019-05-16 Compositions for inducing an immune response

Publications (1)

Publication Number Publication Date
MX2020012150A true MX2020012150A (es) 2021-04-28

Family

ID=62623405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012150A MX2020012150A (es) 2018-05-16 2019-05-16 Composiciones para inducir una respuesta inmunitaria.

Country Status (11)

Country Link
US (1) US20210213060A1 (es)
EP (1) EP3793581A1 (es)
JP (2) JP2021528367A (es)
KR (1) KR20210018295A (es)
CN (1) CN112088012A (es)
AU (1) AU2019270424A1 (es)
CA (1) CA3097951A1 (es)
GB (1) GB201807932D0 (es)
MX (1) MX2020012150A (es)
SG (1) SG11202010862VA (es)
WO (1) WO2019219851A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc calr and jak2 mutant-based vaccines and their uses
EP4444347A1 (en) * 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
IN2015DN03326A (es) * 2012-10-28 2015-10-09 Bavarian Nordic As

Also Published As

Publication number Publication date
CN112088012A (zh) 2020-12-15
US20210213060A1 (en) 2021-07-15
JP2024105526A (ja) 2024-08-06
JP2021528367A (ja) 2021-10-21
EP3793581A1 (en) 2021-03-24
GB201807932D0 (en) 2018-06-27
CA3097951A1 (en) 2019-11-21
WO2019219851A1 (en) 2019-11-21
SG11202010862VA (en) 2020-11-27
AU2019270424A1 (en) 2020-11-19
KR20210018295A (ko) 2021-02-17

Similar Documents

Publication Publication Date Title
MX2020012150A (es) Composiciones para inducir una respuesta inmunitaria.
PH12018501628A1 (en) Optimized factor viii genes
PE20211859A1 (es) Composiciones y metodos para aumentar o mejorar la transduccion de vectores de terapia genetica y para eliminar o reducir las inmunoglobulinas
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2019006725A (es) Polinucleotidos y polipeptidos de adenovirus.
MX2022009962A (es) Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2.
HRP20211601T1 (hr) Rekombinantni proteini bez fenilalanina (phe) za liječenje fenilketonurije
MX2021009357A (es) Dianas de genes de combinacion para mejorar la inmunoterapia.
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
NZ602897A (en) Raav-guanylate cyclase compositions and methods for treating leber’s congenital amaurosis-1 (lca1)
ATE420653T1 (de) Von tryptophanyl-trna-synthetase stammende polypeptide zur regulierung der angiogenese
MX2022011394A (es) Composiciones y metodos para la induccion de una respuesta inmune.
WO2018234506A3 (en) PERSONALIZED VACCINE
MX2019009551A (es) Enzima lipolitica para usarse en horneado.
MX2020013553A (es) Polinucleotidos y polipeptidos de adenovirus.
MX2021005555A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.
MX2021014856A (es) Vacuna de tgf-beta.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2022011673A (es) Nuevos marcadores de superficie celular recombinantes.
WO2021026488A3 (en) Use of pcbp1 to generate induced pluripotent stem cells while inhibiting oncogenesis
AU2018244677A1 (en) Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane
MX2022007237A (es) Variante del virus de la vacuna oncolitica y metodos de uso del mismo.
JOP20210067A1 (ar) ناقلات العلاج الجيني kir 7.1 وطرق استخدامها
MX2022000725A (es) Anticuerpos potenciadores del factor h y usos de estos.